Lilly posts explosive Q1 2026 results

Lifts full-year outlook as obesity drug boom accelerates

Gilead completes $7.8B Arcellx acquisition & takes full control of Myeloma CAR-T candidate

Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right

ProBioGen appoints Dr Simon Johannes Bulling as its new Chief Operating Officer

Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Max Institute of Cancer Care, Vaishali showcases advanced oncology technologies at ONCO-CON 2026

The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care

Orca Bio’s Orca-T FDA review extended to July 2026

Cbio launches first-in-human trial for groundbreaking cervical cancer therapy

Liberate Bio bags key CAR-M patents, eyes first clinical trials in 2026

The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations

MGM Hospitals deliver life-saving CAR-T therapy to elderly cancer patients in Chennai

A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer

Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy

Arcellx develops innovative immunotherapies for cancer and other incurable diseases